Pharmacokinetics and effects of propranolol in terminal uraemic patients and in patients undergoing regular dialysis treatment
- PMID: 1017154
- DOI: 10.2165/00003088-197601050-00004
Pharmacokinetics and effects of propranolol in terminal uraemic patients and in patients undergoing regular dialysis treatment
Abstract
Propranolol blood and plasma levels were measured after a single oral dose of 40 mg in patients with chronic renal failure, in patients undergoing regular dialysis treatment, and in healthy volunteers. Peak levels were observed in all cases within 1.5 to 3 hours. However, peak blood and plasma concentrations of propranolol in the chronic renal failure group were 2- to 3-fold higher (161 +/- 41 ng/ml) than those observed in the dialysis patients (47 +/- 9 ng/ml) and in the healthy volunteers (26 +/- 1 ng/ml). The apparent plasma clearance was also significantly reduced in the patients with chronic renal failure. The data suggest a reduced hepatic extraction in chronic renal failure patients. A significant increase in the fraction of the dose available to the systemic circulation was also found, together with a modification of apparent plasma half-life and volume of distribution in regular dialysis patients during the dialysis day as compared with the after-dialysis day. No extraction of propranolol by the dialyzer was noticed. Marked fluctuations in propranolol blood concentrations were also observed in patients on regular dialysis following continuous propranolol treatment. The suppressive effect of propranolol on plasma renin activity did not fully correlate with the hypotensive effect of the drug. On the basis of the reported data, propranolol should be used with great caution and at low doses in chronic renal failure.
Similar articles
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
-
Effect of dose and uremia on plasma and urine profiles of propranolol metabolites.Clin Pharmacol Ther. 1980 Jun;27(6):744-55. doi: 10.1038/clpt.1980.105. Clin Pharmacol Ther. 1980. PMID: 7379441
-
Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients.Thromb Haemost. 1997 Apr;77(4):650-5. Thromb Haemost. 1997. PMID: 9134637
-
Reduced extraction of I-propranolol by perfused rat liver in the presence of uremic blood.J Pharmacol Exp Ther. 1985 May;233(2):277-84. J Pharmacol Exp Ther. 1985. PMID: 3999018
-
Pharmacokinetics of propranolol: a review.Postgrad Med J. 1976;52 Suppl 4:22-25. Postgrad Med J. 1976. PMID: 787953 Review.
Cited by
-
Pharmacokinetics of l-propranolol during repetitive dosing in normal and uranyl nitrate-induced renal failure rats.J Pharmacokinet Biopharm. 1984 Oct;12(5):479-93. doi: 10.1007/BF01060127. J Pharmacokinet Biopharm. 1984. PMID: 6520744
-
Prazosin: a review of its pharmacological properties and therapeutic efficacy in hypertension.Drugs. 1977 Sep;14(3):163-97. doi: 10.2165/00003495-197714030-00002. Drugs. 1977. PMID: 143363 Review. No abstract available.
-
Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency.Clin Pharmacokinet. 1996 Aug;31(2):111-9. doi: 10.2165/00003088-199631020-00003. Clin Pharmacokinet. 1996. PMID: 8853933 Review.
-
Elimination kinetics of labetalol in severe renal failure.Br J Clin Pharmacol. 1982 Jun;13(1 Suppl):81S-86S. doi: 10.1111/j.1365-2125.1982.tb01893.x. Br J Clin Pharmacol. 1982. PMID: 7093103 Free PMC article.
-
Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations.Clin Pharmacokinet. 1984 Jan-Feb;9(1):42-66. doi: 10.2165/00003088-198409010-00003. Clin Pharmacokinet. 1984. PMID: 6362952 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical